YOLFTbeta
Vectus Biosystems Ltd

Vectus Biosystems Ltd

VBS · AU · Healthcare / Biotechnology

0.053AUD+0.00 (+6.00%)

Price History

Full chart

Market Stats

Previous Close0.05
Open0.052
Day Range0.052 – 0.055
52-Week Range0.074 – 0.455
Volume79.00K
Market Cap6.22M
P/E (TTM)3.33
Forward P/E0.00
EPS0.03
Dividend Yield0.00%
Beta0.51
50-Day Avg0.1469
200-Day Avg0.1409

About

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Tara Speranza
  • Employees0
  • Headquarters26-34 Dunning Avenue, Rosebery, NSW, Australia, 2018, Australia
  • Websitehttps://www.vectusbiosystems.com.au

Leadership

  • Dr. Tara SperanzaCEO & CTO
  • Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFinCompany Secretary
  • Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D.Consultant

Financials

Income Statement

Currency: AUD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue-659.72K872.23K2.95K75.07K49.34K1.83K22051.19K1801.30M1.35M1.14M478.18K-
Growth (%)--+32.21%-99.66%+2443.75%-34.28%-96.30%-87.96%+23166.36%-99.65%+722167.22%+4.19%-15.94%-58.01%-
Cost of Revenue76.82K-0264.28K57.34K020.10K22.63K19.52K-1.02M20.19K47.21K58.84K13.69K4.60K
Gross Profit-76.82K659.72K872.23K2.95K17.72K49.34K-18.27K-22.41K31.67K1.02M1.28M1.31M1.14M478.18K-4.60K
Gross Margin-100.00%100.00%100.00%23.61%100.00%-1000.16%-10185.00%61.87%565552.78%98.45%96.51%100.00%100.00%-
Operating Expense1.78M1.92M2.35M2.41M4.04M4.87M3.98M2.35M2.75M4.82M5.88M5.91M3.41M2.17M1.36M
Operating Income-1.86M-1.26M-1.48M-2.41M-4.02M-4.82M-3.99M-2.37M-2.71M-3.80M-4.60M-4.60M-2.27M-1.69M-1.37M
Operating Margin--190.83%-169.30%-81532.50%-5358.54%-9761.81%-218652.98%-1078763.64%-5303.31%-2113772.22%-353.85%-339.44%-199.41%-352.95%-
EBITDA-1.75M-1.70M-1.42M-2.26M-3.89M-4.79M-3.97M-2.35M-2.64M-3.71M-3.28M-3.19M-2.27M-1.69M-1.36M
EBITDA Margin--257.10%-162.91%-76611.86%-5182.15%-9704.65%-217452.87%-1068377.27%-5165.18%-2058868.33%-252.30%-235.44%-199.41%-352.95%-
Net Income-1.43M-1.24M-1.48M-1.66M-3.21M-3.79M-2.59M-1.60M-3.00M-3.86M-3.99M-3.45M-2.34M-1.78M1.56M
Net Income Margin--187.64%-169.92%-56111.49%-4277.57%-7690.48%-141614.45%-725581.82%-5853.30%-2145135.56%-307.19%-254.62%-205.34%-371.67%-
R&D317.68K26.25K288.32K759.14K1.48M2.26M1.60M711.80K713.00K1.72M2.54M1.96M1.15M667.81K173.00K
R&D as % of Total Revenue-3.98%33.06%25724.81%1977.79%4573.65%87718.06%323544.09%1392.96%952954.44%195.04%144.52%101.09%139.66%-
Interest Expense18.47K05.43K012.00K2.44K23.46K123.17K716.34K1.07M693.49K205.52K8.70K3.91K44.07K
Interest Expense % of Total Revenue-0.00%0.62%0.00%15.99%4.94%1283.91%55984.09%1399.47%596816.11%53.34%15.17%0.76%0.82%-

Balance Sheet

Currency: AUD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets672.80K1.49M717.98K11.73M4.68M720.55K196.28K194.11K3.00M6.98M3.94M4.63M2.03M782.66K3.82M
Total Liabilities1.18M515.93K662.45K510.57K935.75K603.99K2.45M3.92M9.71M9.88M8.36M1.11M539.26K1.04M1.50M
Total Equity-504.57K976.04K55.53K11.22M3.75M116.56K-2.26M-3.73M-6.71M-2.90M-4.42M3.52M1.49M-256.62K2.32M
Cash341.14K1.26M70.06K11.58M421.00K516.91K41.81K43.17K2.69M5.78M1.28M2.95M808.97K250.99K718.59K
Total Debt739.59K26.14K47.03K5.38K5.00K-912.00K1.97M8.28M8.68M6.90M70.21K28.93K200.00K546.66K
Net Debt398.45K-1.23M-23.03K-11.58M-416.00K-516.91K870.19K1.92M5.60M2.90M5.62M-2.88M-780.04K-50.99K-171.93K

Cash Flow

Currency: AUD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-1.41M-1.12M-1.29M-1.64M-2.61M-3.89M-1.39M-1.04M-3.00M-3.26M-4.44M-2.35M-2.03M-830.09K-573.39K
Investing Cash Flow-131.20K-6.62K-34.84K-43.39K-4.12M3.99M0-21.00K-21.00K-21.00K-21.00K-17.13K-67.90K101.03K-
Financing Cash Flow949.76K2.04M542.40K3.76M4.74M-5.38K912.00K1.04M5.64M6.35M-34.55K4.04M-41.28K171.07K1.04M
Capital Expenditure131.20K6.62K34.84K9.40K82.00K39.28K021.00K21.00K221.00K17.13K67.90K25
Free Cash Flow-1.54M-1.13M-1.33M-1.65M-2.69M-3.93M-1.39M-1.04M-3.00M-3.26M-4.46M-2.37M-2.10M-830.09K-573.40K
Dividends Paid----4.57M---6.89M6.26M4.10M4.03M---
FCF to OCF109.32%100.59%102.69%100.57%103.14%101.01%100.00%100.00%100.00%100.00%100.47%100.73%103.34%100.00%100.00%
Dividend Paid to FCF-----169.63%----229.44%-192.23%-91.78%-170.15%---

Earnings

Report DateFeb 3, 2016Sep 30, 2016Oct 1, 2016Feb 28, 2017Sep 28, 2017Feb 28, 2018Aug 31, 2018Feb 28, 2019Aug 30, 2019Feb 28, 2020Aug 31, 2020Feb 26, 2021Aug 31, 2021Feb 25, 2022Aug 31, 2022Feb 24, 2023Feb 21, 2025Aug 29, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.00--0.000.00
EPS Actual-0.05-0.11-0.11-0.07-0.10-0.04-0.07-0.02-0.07-0.04-0.08-0.09-0.07-0.08-0.04-0.05-0.02-0.01
Surprise------------------
Timing-------------Pre-marketAfter-hoursAfter-hours--

Key Statistics & Ratios

Market Cap6.22M
Enterprise Value4.49M
Trailing P/E3.33
Forward P/E0.00
Price / Sales2.25
Price / Book3.22
EPS0.03
Book Value0.038
Revenue (TTM)2.77M
Gross Profit (TTM)2.77M
EBITDA1.40M
Profit Margin56.33%
Operating Margin76.36%
Return on Equity139.32%
Return on Assets37.42%
Shares Outstanding62.18M
Shares Float28.64M
Beta0.51
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%